| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,890,000 |
| Market
Cap: |
37.18(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.51 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
122,000 |
248,000 |
500,000 |
584,000 |
| Total Sell Value |
$252,439 |
$623,979 |
$2,056,681 |
$2,685,347 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
5 |
11 |
27 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Desai Neil |
Executive Chairman |
• • • |
2023-06-02 |
4 |
AS |
$7.99 |
$99,421 |
I/I |
(12,443) |
1,814,118 |
|
-46% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-06-01 |
4 |
AS |
$7.92 |
$39,468 |
I/I |
(4,982) |
1,826,561 |
|
-42% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-05-04 |
4 |
AS |
$7.57 |
$17,445 |
I/I |
(2,305) |
1,831,543 |
|
-22% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-05-03 |
4 |
AS |
$7.68 |
$59,073 |
I/I |
(7,695) |
1,833,848 |
|
-23% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-05-02 |
4 |
AS |
$7.48 |
$56,225 |
I/I |
(7,521) |
1,841,543 |
|
-24% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-05-01 |
4 |
AS |
$7.80 |
$190,895 |
I/I |
(24,479) |
1,849,064 |
|
-34% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-04-06 |
4 |
AS |
$7.09 |
$86,616 |
I/I |
(12,212) |
1,873,543 |
|
-16% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-04-05 |
4 |
AS |
$7.24 |
$53,076 |
I/I |
(7,336) |
1,885,755 |
|
-17% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-04-04 |
4 |
AS |
$7.30 |
$93,981 |
I/I |
(12,869) |
1,893,091 |
|
-19% |
|
| Desai Neil |
Executive Chairman |
• • • |
2023-04-03 |
4 |
AS |
$7.45 |
$71,355 |
I/I |
(9,583) |
1,905,960 |
|
-21% |
|
| Dalal Anupam |
Director |
– • – |
2022-09-26 |
4 |
A |
$12.50 |
$4,000,000 |
I/I |
320,000 |
1,849,402 |
|
- |
|
| Giacobello Scott M. |
Chief Financial Officer |
• – – |
2022-09-26 |
4 |
A |
$12.50 |
$250,000 |
D/D |
20,000 |
20,000 |
|
- |
|
| Delaney Brendan |
Chief Operating Officer |
• – – |
2022-09-26 |
4 |
A |
$12.50 |
$250,000 |
D/D |
20,000 |
20,000 |
|
- |
|
| Castelein Caley |
Director |
– • – |
2022-09-26 |
4 |
A |
$12.50 |
$3,000,000 |
I/I |
240,000 |
499,998 |
|
- |
|
| Avoro Ventures Llc |
See Remarks |
– • • |
2022-09-22 |
4 |
A |
$12.50 |
$15,750,000 |
I/I |
1,260,000 |
3,471,752 |
|
- |
|
| Desai Neil |
See Remarks |
• • • |
2022-03-18 |
4 |
AS |
$20.07 |
$71,234 |
I/I |
(3,550) |
1,915,543 |
|
-33% |
|
| Itri Lorettta M |
Chief Medical OfficerOfficer |
• – – |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,000 |
|
-37% |
|
| Desai Neil |
See RemarksOfficer |
• • – |
2021-08-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,558,791 |
|
-34% |
|
| Avoro Ventures Llc |
Director |
– • – |
2021-08-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
300,000 |
|
-34% |
|
| Castelein Caley |
Director |
– • – |
2021-08-26 |
4 |
B |
$13.08 |
$3,399,994 |
I/I |
259,998 |
259,998 |
2.1 |
-34% |
|
| Dalal Anupam |
Director |
– • – |
2021-08-26 |
4 |
B |
$13.08 |
$19,999,990 |
I/I |
1,529,402 |
1,529,402 |
2.1 |
-34% |
|
| Avoro Ventures Llc |
See Remarks |
– – – |
2021-08-26 |
4 |
A |
$13.08 |
$24,999,981 |
I/I |
1,911,752 |
2,211,752 |
|
- |
|
| Castelein Caley |
Director |
– • – |
2021-06-30 |
4 |
A |
$1.52 |
$11,873 |
D/D |
7,811 |
295,414 |
|
- |
|
| Cohen Cheryl |
Director |
– • – |
2021-06-30 |
4 |
A |
$1.52 |
$12,373 |
D/D |
8,140 |
16,160 |
|
- |
|
| Dugel Pravin |
Director |
– • – |
2021-06-30 |
4 |
A |
$1.52 |
$9,623 |
D/D |
6,331 |
12,568 |
|
- |
|
138 Records found
|
|
Page 2 of 6 |
|
|
0.10 (5.32%) 
